Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sarepta Therapeutics Inc    SRPT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Sarepta Therapeutics Inc : SRPT, FB, CRUS and OMER added to NASDAQ Active Stock Watch List at GSR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/24/2013 | 03:05pm CET

New York, NY - (ACCESSWIRE) - 09/24/2013 - Growing Stock Report initiates its NASDAQ Active Stock Watch List adding Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Facebook, Inc. (NASDAQ:FB), Cirrus Logic Inc. (NASDAQ:CRUS), and Omeros Corporation (NASDAQ:OMER)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) a biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases closed up in its previous session (+10.79%) on 6,581,320 shares traded after Sarepta was upgraded to Overweight from Neutral at Piper Jaffray. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is currently up (+251.61%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=SRPT&SubId=AW

Facebook, Inc. (NASDAQ:FB) operates as a social networking company worldwide closed down in its previous session (-0.63%) on 75,274,915 shares traded after Facebook Quietly Rolls Out Its Mobile Payments Autofill Product, AllThingsD Reported. Facebook, Inc. (NASDAQ:FB) is currently down (-2.75%) from its recent 52-week high, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Facebook, Inc. (NASDAQ:FB)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=FB&SubId=AW

Cirrus Logic Inc. (NASDAQ:CRUS) a fabless semiconductor company that develops analog and mixed-signal integrated circuits for a range of consumer and industrial markets closed up in its previous session (+5.41%) on 6,219,309 shares traded after CIRRUS LOGIC INC Filed SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year. Cirrus Logic Inc. (NASDAQ:CRUS) is currently up (+46.96%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Cirrus Logic Inc. (NASDAQ:CRUS)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=CRUS&SubId=AW

Omeros Corporation (NASDAQ:OMER) a clinical-stage biopharmaceutical company that engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system closed up in its previous session (+28.21%) on 8,095,031 shares traded after Omeros has been Chosen to Present at NewsMakers in the Biotech Industry 2013 Conference on Friday, September 27, 2013. Omeros Corporation (NASDAQ:OMER) is currently up (+167.95%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Omeros Corporation (NASDAQ:OMER)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=OMER&SubId=AW

GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed. Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.GrowingStockReport.com

Disclosure: GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.

Contact Info:
Growing Stock Report
editor@GrowingStockReport.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SAREPTA THERAPEUTICS INC
12/01 SAREPTA THERAPEUTICS : Announces Inducement Grants Under Nasdaq Listing Rule 563..
11/24 SAREPTA THERAPEUTICS : U.S. Patents Awarded to Inventors in Vermont (Nov. 24)
11/24 SAREPTA THERAPEUTICS : Assigned Patent
11/17 SAREPTA THERAPEUTICS : to Present Company Overview at the Credit Suisse 25th Ann..
11/17 SAREPTA THERAPEUTICS : Patent Issued for Immunosuppression Compound and Treatmen..
11/10 SAREPTA THERAPEUTICS : Announces Inducement Grants Under Nasdaq Listing Rule 563..
11/10 SAREPTA THERAPEUTICS : Assigned Patent
11/07 SAREPTA THERAPEUTICS : Management's Discussion and Analysis of Financial Conditi..
11/04 SAREPTA THERAPEUTICS : to Present Company Overview at the Credit Suisse 25th Ann..
11/03 SAREPTA THERAPEUTICS : to Announce Third Quarter 2016 Financial Results and Rece..
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
12/02 Sarepta's Twin Sister
11/01 Going Long Sarepta Is A Calculated Risk, And We're Taking It
10/29 Sarepta Therapeutics' (SRPT) CEO Edward Kaye on Q3 2016 Results - Earnings Ca..
10/28 Healthcare ratings roundup - new coverage
10/27 Sarepta beefs up cash position in Q3 to support EXONDYS 51 launch; quick asse..
Advertisement
Financials ($)
Sales 2016 26,0 M
EBIT 2016 -218 M
Net income 2016 -225 M
Finance 2016 284 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 57,7x
EV / Sales 2017 7,51x
Capitalization 1 783 M
More Financials
Chart SAREPTA THERAPEUTICS INC
Duration : Period :
Sarepta Therapeutics Inc Technical Analysis Chart | SRPT | US8036071004 | 4-Traders
Full-screen chart
Technical analysis trends SAREPTA THERAPEUT...
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 71,5 $
Spread / Average Target 119%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Edward M. Kaye President, Chief Executive & Medical Officer
M. Kathleen Behrens Chairman
Gavin T. Malenfant Head-Operations & Vice President
Sandesh Mahatme Chief Financial Officer & Senior Vice President
Gil Price Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SAREPTA THERAPEUTICS I..-11.20%1 783
AMGEN, INC.-11.25%107 132
GILEAD SCIENCES, INC.-27.17%95 410
CELGENE CORPORATION-1.78%91 187
REGENERON PHARMACEUTIC..-31.34%39 310
ACTELION LTD40.40%21 739
More Results